Ocera Therapeutics, Inc. is a clinical stage biopharmaceutical company. It engages in development and commercialization of OCR-002 (ornithine phenylacetate0 in intravenous and oral formulations. The company was founded by Wu Xiaoyun, John C. Kappes, and Eckard Weber on January 12, 1998 and is headquartered in Palo Alto, CA.
